What we do Sudarshan Pharma Industries Ltd specializes in specialty chemicals, pharmaceutical APIs, intermediates, and generic formulations, with exports mainly to South East Asia, Middle East, and North Africa. |
Founded in 2,008 |
Market share Emerging player with focused growth in specialty chemicals and pharmaceuticals in domestic and international markets. |
Problem solved Addresses supply chain risks by producing pharmaceutical ingredients, reducing dependence on imports, ensuring cost-effective and reliable raw material availability. |
Top clients or who we serve Serves healthcare institutions, government agencies, NGOs, hospitals, and industrial sectors in pharma, paints, food, and adhesives; B2B and B2C. |
Key management Hemal V. Mehta (Chairman & Managing Director), Sachin V. Mehta (Joint Managing Director & CFO). |
Our journey and innovations Founded in 2008, transitioned public in 2017, expanded into nutraceuticals, acquired subsidiaries, developed Vitamin B1 & B6 molecules, and launched own pharma brands. |
Where we operate India, with exports focused on South East Asia, Middle East, North Africa, and plans for expansion including Singapore and Dubai subsidiaries. |
Top products or what we offer Specialty chemicals, pharmaceutical intermediates, APIs, generic pharma formulations, contract manufacturing, and nutraceuticals. |
Top brands Setdown, Pulmo Relief, Fix Pollen, Flupimac; over 100 generic pharma products under own and partner brands. |
Raw materials needed Pharmaceutical intermediates, specialty chemicals, raw materials for APIs and formulations. |
Raw materials supplier Various Indian and international suppliers with FDA and WHO-approved plants. |
Recurring vs cyclical contribution Major revenue from recurring supplies and contract manufacturing; cyclical exposure to pharma industry dynamics. |
Our industry position Growing mid-sized player with increasing presence in specialty chemical and generic pharma domains domestically and in select export markets. |
Financial highlights FY25 revenue Rs 505 Cr, PAT Rs 15.96 Cr, EBITDA growth 67%, 9% revenue growth year-on-year, EPS Rs 0.66. |
Geographical revenue split Mainly India and exports to South East Asia, Middle East, North Africa; strategic warehouses in Maharashtra and Himachal Pradesh. |
Order book - |
Whats driving growth Vertical integration, new unit capacity, strategic acquisitions, increasing exports, and focus on innovation and proprietary pharma products. |
Our future plans Expansion in API manufacturing, nutraceuticals plant, product development in vitamins, global market expansion via subsidiaries. |
Our green promise - |
Our people and values Professional board and management promoting ethical marketing, compliance, and employee development. |
Key challenges ahead Managing supply chain dependencies, regulatory compliance, expanding manufacturing capabilities, and competition in pharma ingredients market. |
Interesting facts First Indian firm from the company developing Vitamin B1 and Vitamin B6 molecules in-house. Listed on BSE SME platform in 2023. |
Risks and strategy Mitigates import risks by R&D and vertical integration; focuses on diverse client base and geographic markets to sustain growth. |
